Heinz is an Immunologist and Professor Emeritus at Harvard Medical School. Heinz originally trained at the University and Medical School in Munich, receiving an M.D. and a Ph.D. in Zoology. He did postdoctoral research in protein structure at the University of Würzburg and then in Boston at the Robert Breck Brigham Hospital where he and his postdoctoral mentor Dr. John David made numerous contributions to the (then) emerging field of protein mediators/cytokines, especially migration inhibitory factor (MIF). Heinz was appointed to the faculty at Harvard Medical School becoming Full Professor in 1983 in the Department of Medicine.

He joined the Rheumatology Division of the Brigham and Womens’ Hospital where he established a lab focusing on the immunology and biochemistry of monocytes/macrophages and their interactions with lipid and protein modulators, areas where he has become a recognized expert. He identified immune receptors for glycolipids and proteases such as plasminogen activator. He clarified the antagonistic effects of eicosanoid lipid mediators, the prostaglandins and lipoxins as positive and negative modulators, respectively, of macrophage activation. Dr. Remold is well known for his contributions to understanding immune protection against the infectious agent of tuberculosis, Mycobacterium tuberculosis, which uses lung macrophages as initial host cells, making macrophages particularly prominent in prevention of progression to disease. Heinz has been a pioneer in championing the importance of cell death modality on the outcome of infection. Further, Heinz helped elucidate the signaling pathway leading to necrosis on infection with virulent mycobacteria. In addition, Heinz is highly active as an ornithologist. Dr. Heinz Remold will advise and oversee basic and translational research at Edelweiss Immune.  The name of “Edelweiss Immune” was originally suggested by Dr. Heinz Remold.